Several innovative disease-modifying treatments (DMTs) for relapsing-remitting multiple
sclerosis have been licensed recently or are in late-stage development. The molecular
targets of several of these DMTs are well defined. All affect at least 1 of 4 properties, namely
(1) trafficking,(2) survival,(3) function, or (4) proliferation. In contrast to β-interferons and
glatiramer acetate, the first-generation DMTs, several newer therapies are imbued with
safety issues, which may be attributed to their structure or metabolism. In addition to efficacy …